期刊文献+

胰腺癌神经浸润及临床研究新进展 被引量:7

Research progress of neural invasion of pancreatic cancer
原文传递
导出
摘要 胰腺癌的特点是神经浸润非常高发(可高达90%~100%),这与其生存率不高有关。肿瘤细胞胰内、胰外神经浸润是胰腺癌神经变化的典型表现。胰外神经丛浸润增加可以促进胰内神经浸润的发生,从而造成疼痛。胰腺癌诊断率的显著增加与新发糖尿病的诊断有关,高血糖也有促进胰腺癌神经浸润的可能。控制高血糖和光基因技术可作为胰腺癌神经浸润的辅助治疗,并且可以利用光基因技术对胰腺癌的神经浸润进行监测。 The high occurrence of neural invasion in pancreatic carcinoma, which can be as much as 90%-100%, leads to the poor survival rate in patients. The classical pathology includes invasion of both the extrapancreatic and intrapancreatic neurons. Metastasis into the extrapancreatic plexus promotes invasion into the intrapancreatic neurons and therefore results in pain. An increased in the diagnosis of new-onset diabetes mellitus, on the other hand, correlates with an increase in pancreatic cancer. This implies that hyperglycemia may promote neural invasion of pancreatic carcinoma. Novel auxiliary therapy of pancreatic carcinoma with neural invasion includes controlling of blood sugar and optogenetics, a new genetic technology which can further be utilized for surveillance.
出处 《中华肝胆外科杂志》 CAS CSCD 北大核心 2011年第6期515-517,共3页 Chinese Journal of Hepatobiliary Surgery
关键词 胰腺癌 神经浸润 疼痛 高血糖 光基因技术 Pancreatic cancer Perineural invasion Pain Hyperglycemia Optogenentics
  • 相关文献

参考文献5

二级参考文献51

  • 1Bardeesy N,DePinho RA.Pancreatic cancer biology and genetics.Nat Rev Cancer,2002,2:897-909.
  • 2Bockman DE,Guo J,Buchler P,et al.Origin and development of the precursor lesions in experimental pancreatic cancer in rats.Lab Invest,2003,83:853-859.
  • 3Hruban RH,Goggins M,Parsons J,et al.Progression model for pancreatic cancer.Clin Cancer Res,2000,6:2969-2972.
  • 4Halloran CM,Ghaneh P,Neoptolemos JP,et al.Gene therapy for pancreatic cancer-current and prospective strategies.Surg Oncol,2000,9:181-191.
  • 5Sakorafas GH,Tsiotos GG.Molecular biology of pancreatic cancer:potential clinical implications.Bio Drugs,2001,15:439-452.[6] Ramirez PJ,Vickers SM.Current status of gene therapy for pancreatic cancer.Curt Surg,2004,61:84-92.
  • 6Perez RP,Smith JW,Alberts SR,et al.A phase Ⅱ trial of ISIS 2503,an antisense inhibitor of H-ras,in patients with advanced pancreatic carcinoma.Proc Am Soc Clio Oncol,2001[Abstr 628].
  • 7Butch PA,Alberts SR,Schroeder MT,et al.Gemeitabine and ISIS-2503 for patients with pancreatic adenocarcinoma:a North Central Cancer Treatment Group(NCCTG)phase Ⅱ trial.Proc Am Soc Clin Oncol,2003[Abstr 1038].
  • 8Oeker M,Neureiter D,Leuders M,et al.Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer.Gut,2005,54:1298-1308.
  • 9Duda DG,Sunamura M,Lefter LP,et al.Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcionma cells.Oncogene,2003,22:6857-6864.
  • 10Galanis E,Carlson SK,Foster NR,et al.Phase Ⅰ trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.Mol Ther,2008,16:979-984.

共引文献186

同被引文献49

引证文献7

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部